Prostate Cancer

No Survival Benefit With Cabozantinib in Progressive mCRPC

No Survival Benefit With Cabozantinib in Progressive mCRPC

Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.

Metastatic Prostate Cancer Cases Increasing

Metastatic Prostate Cancer Cases Increasing

Research emphasizes the need for nationwide refinements in the prostate cancer screening process.

PD-1 Blockade Shows Promise for mCRPC

PD-1 Blockade Shows Promise for mCRPC

By

In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.

Prostate Multiparametric MRI Feasible for PCa Screening

Prostate Multiparametric MRI Feasible for PCa Screening

Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.

Robot-Assisted Prostate Surgery Safe, Effective Long Term

Robot-Assisted Prostate Surgery Safe, Effective Long Term

By

Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.

Familial Risk of Aggressive Prostate Cancer Quantified

Familial Risk of Aggressive Prostate Cancer Quantified

By

Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.

Prostate Cancer Patients Taking Statins Lived Longer

Prostate Cancer Patients Taking Statins Lived Longer

Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

By

Preliminary findings suggest a field effect in prostate cancer.

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.

Expectant Management for PCa More Likely at Academic Centers

Expectant Management for PCa More Likely at Academic Centers

By

Odds of using this strategy are 2.7-fold greater vs community facilities.

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

By

Genetic testing results could help guide therapy for advanced prostate cancer.

Hypofractionated RT Noninferior for Localized Prostate Cancer

Hypofractionated RT Noninferior for Localized Prostate Cancer

For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

By

About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.

Prostate Cancer Diagnoses Decreased From 2011 to 2013

Prostate Cancer Diagnoses Decreased From 2011 to 2013

Use of active surveillance increasing, active treatment decreasing for low-risk disease.

Robotic vs Open Prostatectomy Provides Early Benefits for pT2

Robotic vs Open Prostatectomy Provides Early Benefits for pT2

Reduced risk of positive surgical margins versus open prostatectomy for patients with pT2 disease only.

ADT Plus Radiation Improves Survival in Metastatic Prostate Cancer

ADT Plus Radiation Improves Survival in Metastatic Prostate Cancer

Superior median, 5-year OS for prostate RT plus ADT versus ADT alone in propensity score analyses.

Smokers Face Delayed Continence Recovery After Prostate Surgery

Smokers Face Delayed Continence Recovery After Prostate Surgery

By

Large prostates and bladder neck sparing also predict longer time to return of continence.

Testosterone Replacement Safe for Men With Prostate Cancer

Testosterone Replacement Safe for Men With Prostate Cancer

By

Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.

Visceral Fat Predicts Prostate Cancer Treatment Outcomes

Visceral Fat Predicts Prostate Cancer Treatment Outcomes

By

Greater visceral adipose tissue volume and density are associated with a lower the risk of biochemical recurrence.

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

By

Radiation therapy also is associated with a greater likelihood of fractures.

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Does not improve overall survival in metastatic castration-resistant prostate cancer.

PSA of ≥0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

By

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

Record Numbers of Americans Are Cancer Survivors

Record Numbers of Americans Are Cancer Survivors

More effective tools are needed to support the long-term recovery of patients who survive cancer.

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

TRUS-biopsy Inferior for Prostate Cancer Detection

TRUS-biopsy Inferior for Prostate Cancer Detection

Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.

Sign Up for Free e-newsletters